Deletions or monosomy of chromosome 13 are frequent in multiple myeloma (MM). A candidate tumor suppressor gene might reside telomeric of the retinoblastoma gene (RBI) at band 13q14 and to play a role in B cell neoplasm. The D13S319 locus, between RB1 and D13S25 loci at 13q14 is the most commonly deleted marker in chronic lymphocytic leukemia (CLL) and nonHodgkin's lymphoma (NHL). We evaluated the D13S319 locus in 24 MM cases by fluorescence in situ hybridization (FISH). We observed monosomy for D13S319 in 6/20 (30%) MM patients with an apparently normal karyotype. As expected, in four karyotypically abnormal MM cases with partial or complete monosomy for chromosome 13, all of them had monoallelic loss of D13S319. Our results indicated that the loss of D13S319 is commonly found in MM, even at diagnosis, and is more frequent than predicted based on conventional cytogenetic analysis of metaphase spreads. This finding implicates a candidate tumor suppressor gene at 13q14 in the pathogenesis of MM.
Introduction
Multiple myeloma (MM) is a terminally differentiated clonal B cell tumor that usually has minimal proliferative activity. 1 Conventional cytogenetic analysis of MM reveals abnormal karyotypes in 30-45% of de novo cases, and 35-60% in previously treated and relapsing patients. [2] [3] [4] Chromosome analysis is limited, however by the low number of metaphases. Cytogenetic analysis and measurement of DNA content of MM has demonstrated that almost all patients are cytogenetically abnormal. 5 Although flow cytometric studies show a high frequency of DNA aneuploidy (Ͼ80%) in MM and thereby suggest that chromosomal abnormalities may be important, 6 the identity of the critical cytogenetic changes remains unknown.
Fluorescence in situ hybridization (FISH) circumvents the limitations of standard cytogenetics and allows for the detection of numerical and structural chromosomal abnormalities in both metaphase spreads and interphase nuclei. 7 Thus FISH is an important and direct approach for assessing the incidence of chromosomal aberrations of MM. [8] [9] [10] Deletions and monosomy of chromosome 13 are common cytogenetic abnormalities in MM and are associated with poor prognosis. 11 Tricot et al 11 showed that myeloma patients with either complete or partial deletion of chromosome 13 had significantly lower remission and survival rates. A candidate tumor suppressor gene on chromosome 13 has been recently localized to 13q14.3. 12, 13 The D13S319 locus, located between RB1 gene and D13S25 (Figure 1 ), is frequently deleted in B-CLL and NHL. 14, 15 This suggests that the deletion of a tumor suppressor gene near D13S319, and distal to RB1, is a significant tumorigenic event in these malignancies. However, it is not known whether deletions in this vicinity of chromosome 13 also occur in MM or if such changes contribute to the pathogenesis of this disease. To evaluate the D13S319 region in MM, we used interphase FISH to analyze 24 previously characterized bone marrow cytogenetic specimens from MM patients.
Materials and Methods

Patient samples
Bone marrow samples from 24 MM cases at different clinical stages (Table 1) were collected from our hematology outpatient clinic and transferred directly to the cytogenetics laboratory. Five cytogenetically normal bone marrow samples from a patient with anemia and a bone marrow transplant
Figure 1
Hybridization of D13S319 DNA probe to chromosome 13 from a normal metaphase. Also shown is a map of the minimally deleted region in CLL and its relationship to D13S319 (not accurate to scale). Percentage of interphase nuclei with one signal and interpretation of findings where 'no' indicates absence of deletion, 'yes' indicates a deletion is present. b This value was determined to be statistically significant in comparison to the control series (P Ͻ 0.005).
recipient were used as controls. Samples were processed for cytogenetic and FISH analysis.
G-banding analysis
Both direct (uncultured) and 24-h cultures were harvested using standard protocols. 16 Metaphases were analyzed using GTG method. ISCN criteria were used to define abnormal clones. 17 A sample was classified as cytogenetically abnormal if at least one abnormal clone was characterized with a minimum of 10 cells analyzed. The direct (uncultured) specimen was used first and the 24-h culture used only if the direct specimen was cytogenetically normal or if an inadequate number of metaphases were obtained from the direct specimen.
FISH
Interphase FISH was performed using standard methods. 7 Slides made from the bone marrow samples were prewarmed in 2 × SSC pH 7.0 at 37°C for 30 min. The slides were then dehydrated in an ethanol series, and denatured in a solution of 70% formamide in 2 × SSC at 70°C. Slides were hybridized to a commercially available probe at 37°C in a humidified chamber overnight. The probe was LSI D13S319 (13q14.3), a DNA probe directly labeled with spectrum orange provided by Vysis (Dowers Grove, IL, USA). The slides were then washed with 0.4 × SSC, 0.3% NP-40 at 72°C and with 2 × SSC, 0.1% NP-40. After counterstaining with 4,6 diamino-2-phenylindole (DAPI), the slides were evaluated on an epi-fluorescence microscope. Slides were coded and scored by two independent observers to derive the frequencies of monosomy. Nuclei with only one signal present were scored as monosomic for D13S319. In total, hybridization signals were enumerated in 600 interphase nuclei for each specimen.
Results and discussion
The clinical, immunoglobulin isotype and cytogenetic data of MM patients included in the study are summarized in Table 1 . They were of different clinical stages with various degrees of marrow plasmacytosis. Thirteen (50%) patients were newly diagnosed with MM and had no prior chemotherapy; the remainder had relapsing or progressive disease with at least 3 months of chemotherapy. Seventeen patients had IgG myeloma, four IgA myeloma, and three light chain disease. By conventional cytogenetic analysis 20 patients had normal karyotypes and four had complete or partial monosomy for chromosome 13 in addition to other chromosomal abnormalities ( Table 1) .
The commercially available genomic probe used to detect the presence or absence of the D13S319 locus in interphase nuclei was a 110-140 kb cosmid contig (Vysis). As shown in Figure 1 , the minimally deleted region in CLL is less than 300 kb and has been mapped to band 13q14.3 approximately 100 kb distal to RBI. 18 This region includes D13S319 and D13S272. FISH analysis with D13S319 probe was performed on five control samples and 24 MM patients (Figure 2 ). On average, 4.2% of control nuclei had one signal, presumably resulting from close juxtaposition of independent signals, or inefficient hybridization in those nuclei. 7 This level of background nuclei with one signal is consistent with the expected hybridization efficiencies for this directly labeled commercial probe (information provided by Vysis), and for clinical applications of interphase FISH. 19 A deletion was noted when samples exhibited a greater frequency of interphase nuclei with one D13S319 signal. In all studied cases, less than 0.5% of nuclei had none or three signals. None of the cases included in the study exhibited 'patchy hybridization' on microscope slides, and both the intensity and FISH signal diameter were uniform in all nuclei indicating that the target interphase chromatin was of optimal quality.
Samples that scored positive for a deletion ranging from 11-85% of nuclei. Patients 15-20 had a deletion by interphase FISH despite having a normal karyotype by conventional metaphase analysis. All patients with a cytogenetic monosomy or deletion or chromosome 13 (patients 21-24 in Table 1 ) in their karyotype also scored positive for a deletion of D13S319 by interphase FISH analysis. However, the percentage of interphase nuclei with a deletion in these samples ranged from 17-85%. Our findings indicate that the mitotically active component of the patients' bone marrow may not always be representative of the overall cytogenetic composition. 19 Deviations between metaphase and interphase FISH results suggest that the patient samples often contain a mixture or normal and MM cells, and that one component may be mitotically more active than the other. Alternatively, in some cases of MM it is possible that the proportion of nuclei with one D13S319 signal represents loss of 13 as a secondary change within a neoplastic clone. More detailed studies are required to characterize these observations further.
The presence of chromosome 13 deletions both early and late in the disease course, strongly suggests the involvement of a tumor suppressor gene in the evolution of MM, 1 similar to the observations in CLL. 15 Previous studies have shown that the most common monosomy in MM involves chromosome 13 (14-43%). 8, 11 In this report, we investigated the monoallelic loss of the D13S319 locus on chromosome 13 in MM patients. Using FISH analysis of MM bone marrow cells, our results demonstrated that loss of the region identified by D13S319 was common (30%) in MM patients who appeared karyotypically normal for 13q14. Since our study focused on MM cases with normal karyotypes, the total incidence of monoallelic deletion of D13S319 in MM is therefore likely to be greater than 30%. To our knowledge, this is the first report of such frequent loss of the 13q14.3 region.
We examined several clinical and prognostic factors with respect to the D13S319 deletion in MM cases studied to determine whether any clinical trend was apparent. There was no apparent relationship to tumor stage, immunoglobulin isotype, hemoglobin, serum beta-2 microglobulin level or patient age. A more extensive clinical correlative study would be required to determine whether this deletion was associated with other clinical parameters. Monosomy for D13S319 was observed with similar frequency in patients with or without extensive prior treatment, suggesting that the loss of the D13S319 locus in these patients is a relatively early event in the pathogenesis of MM, and was not induced by chemotherapy. Allelic loss is thought to mark the location of the tumor suppressor gene involved in the pathogenesis and progression of human malignancies. 20 Studies on B-CLL by Liu et al 14 revealed chromosome 13 deletions in 44% of the observed cases. The most commonly deleted region was D13S319, and the smallest region of overlap for the deletions was between RB1 and the D13S25 loci. A more refined localization was performed by others who indicated that at least 40% of B-CLL cases showed a deletion in this region. 15 It has been proposed that a candidate tumor suppressor gene located in the vicinity of D13S319 is involved in the malignant transformation of B-CLL, and our studies suggest this same region may also be involved in MM.
The tumor suppressor gene RB1 has been previously assigned to the 13q14. 21 Loss of the RB1 gene function is involved in the development of retinoblastoma and other solid tumors. [20] [21] [22] Monoallelic RB1 gene deletion by FISH analysis was detected in at least 30% of B-CLL 23 and 50% of MM patients. 24 In B-CLL, a substantial number of patients had homozygous of hemizygous deletions of the 13q14.3 region when D13S25 was used as a marker, but retained the intact RB1 gene. 25 In our MM cases, it is not clear if RB1 is also deleted in those patients with loss of D13S319 locus. However, it is conceivable that deletions of RB1 and the putative tumor suppressor gene at 13q14.3 may both contribute to the pathogenesis of B-CLL and MM. It is well established that allelic loss in this region of chromosome 13 can also be identified by loss of heterozygosity (LOH) analysis (reviewed in Ref. 19) . Diverse chromosomal mechanisms lead to LOH and often generate two genetically identical chromosome 13s in a tumor. In such cases, signal loss will not be detectable by interphase FISH. Future studies should address the incidence of D13S319 deletion in a larger group of MM patients using FISH together with LOH analysis, and evaluate the prognostic significance of such changes.
